Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review

Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review

Hypertriglyceridemia (HTG) is associated with a residual risk of atherosclerotic cardiovascular disease. Extremely elevated triglyceride (TG) concentrations, particularly due to familial chylomicronemia syndrome (FCS), pose a risk for acute pancreatitis. Standard therapies with statins, fibrates, om...

Full description

Bibliographic Details
Main Authors:	Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Pharmaceuticals
Subjects:	hypertriglyceridemia apoC-III ANGPTL3 small interfering ribonucleic acid antisense oligonucleotide FGF21
Online Access:	https://www.mdpi.com/1424-8247/18/2/147

Similar Items

Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia
by: Ivette Cruz-Bautista, et al.
Published: (2021-02-01)

Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans
by: Ewa Karwatowska-Prokopczuk, et al.
Published: (2024-10-01)

Apolipoprotein C3 is negatively associated with estrogen and mediates the protective effect of estrogen on hypertriglyceridemia in obese adults
by: Jinman Li, et al.
Published: (2023-02-01)

Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future
by: Jonathan Hall, et al.
Published: (2022-05-01)

Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia
by: Yitong Xu, et al.
Published: (2022-02-01)

Sex differences in HDL ApoC-III in American Indian youth
by: Blackett Piers R, et al.
Published: (2012-08-01)

Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content
by: Christina Khoo, et al.
Published: (1999-02-01)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
by: Jan Borén, et al.
Published: (2020-07-01)

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
by: Maria Giovanna Lupo, et al.
Published: (2018-07-01)

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice
by: Thomas A. Bell, III, et al.
Published: (2021-01-01)

Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients
by: Caroline Marcoux, et al.
Published: (1999-04-01)

APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries
by: Ye Yang, et al.
Published: (2024-07-01)

Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report
by: Alice Fachin, et al.
Published: (2023-07-01)

ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice
by: Emanuel Voyiaziakis, et al.
Published: (1998-02-01)

Analysis of Use of Antisense Oligonucleotides for Prevention and Treatment of Hazardous and Extremely Hazardous Viral Infectious Diseases
by: A. A. Petrov, et al.
Published: (2020-05-01)

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
by: Christoph Niemietz, et al.
Published: (2015-09-01)

Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
by: Tae Hyun Kim, et al.
Published: (2021-12-01)

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
by: Kurt Sartorius, et al.
Published: (2022-05-01)

Effects of albumin and apolipoprotein C-II on the acyl-chain specificity of lipoprotein lipase catalysis.
by: Chi-Sun Wang, et al.
Published: (1993-12-01)

Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
by: Amalia Despoina Koutsogianni, et al.
Published: (2023-05-01)

Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides
by: Anthony J Hinrich, et al.
Published: (2016-02-01)

Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease
by: Lina Vandermeulen, et al.
Published: (2024-04-01)

Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice
by: Denis Sviridov, et al.
Published: (2023-07-01)

Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma
by: Johan Björkegren, et al.
Published: (1998-07-01)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
by: Lorenza Vantaggiato, et al.
Published: (2022-03-01)

Farnesoid X receptor represses hepatic lipase gene expression
by: Audrey Sirvent, et al.
Published: (2004-11-01)

Assessment of Platelet Aggregation and Thrombin Generation in Patients with Familial Chylomicronemia Syndrome Treated with Volanesorsen: A Cross-Sectional Study
by: Ilenia Lorenza Calcaterra, et al.
Published: (2024-09-01)

Nucleic acid therapeutics: Past, present, and future
by: Sajid Naeem, et al.
Published: (2025-03-01)

A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor
by: Charles L. Bisgaier, et al.
Published: (1998-01-01)

A Tractable and Efficient One-Pot Synthesis of 5'-Azido-5'-deoxyribonucleosides
by: Theodore V. Peterson, et al.
Published: (2014-02-01)

Oligonucleotide Therapeutics: From Discovery and Development to Patentability
by: Lara Moumné, et al.
Published: (2022-01-01)

Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism
by: Huixing Liu, et al.
Published: (2022-02-01)

A perspective on oligonucleotide therapy: Approaches to patient customization
by: Shikha Thakur, et al.
Published: (2022-10-01)

Quantitative fluorescence imaging of antisense oligonucleotide mediated knockdown
by: Chan, Nicholas Zhen Woon
Published: (2024)

Oligonucleotides as a Novel Therapeutic Approach: An Innovative Area for Drug Delivery in Neurological Disorders
by: Yasir Qasim Almajidi, et al.
Published: (2025-01-01)

Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies
by: Shivam Kumar Pandey, et al.
Published: (2022-10-01)

Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics
by: Laura Michelle Streicher
Published: (2021-03-01)

Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients
by: Yu Cui, et al.
Published: (2019-06-01)

Association between apolipoprotein C-III levels and coronary calcification detected by intravascular ultrasound in patients who underwent percutaneous coronary intervention
by: Tatsuya Fukase, et al.
Published: (2024-08-01)

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis
by: M. T. La Chica Lhoëst, et al.
Published: (2024-06-01)